Figure 4.
Change in the number of pain-free days per week with olorinab. Change from baseline in the mean (SD) number of pain-free days per week with olorinab 25 mg TID and olorinab 100 mg TID (A) and in all subjects (B). No subjects experienced a pain-free day at baseline. EOT analysis used the last available value for subjects who withdrew early or did not have week 8 data.
